Engage-hf
Engage-hf has been studied in 1 paper since 2026: 1 trial in people; 1 in the past year. The newest paper, Nov 8, 2026: “A Multicenter Randomized Controlled Trial of a Digital Health Intervention for Medication Optimization in Heart Failure: The ENGAGE-HF Trial Outcomes”.
1 paper studies it2 findingsUpdated
1 new paper in 30 daysSee all 1 papers on engage-hf
At a glance
The findings reach people, from one lab or study. 1 lab.
“At 90 days, the adjusted MOS was significantly higher in the ENGAGE-HF group compared to the control group (83.7% vs. 74.0%, p = 0.010).”
None of its findings points the other way.
- 1 lab
- Funder: American Heart Association
- Human trial1
Studies in people
1 study gave engage-hf to people and measured what changed.
| What changed | Design | People | Source |
|---|---|---|---|
up: Increases medication optimization score83.7% vs. 74.0%; p = 0.010 no change: Has no effect on kansas City Cardiomyopathy Questionnaire Clinical Summary Score75.2 (SE 2.6) vs. 72.2 (SE 2.6); p = 0.40 | Randomized trial90 days | 134 peopleRecently hospitalized patients with heart failure, LVEF <50%, and suboptimal guideline-directed medical therapy | Circulation. Heart failure, Nov 8, 2026 |
What did studies of engage-hf find?
2Studies of engage-hf measured 2 outcomes: kansas City Cardiomyopathy Questionnaire Clinical Summary Score and medication optimization score.
Kansas City Cardiomyopathy Questionnaire Clinical Summary Score
no changein humans1
1 study
Kansas City Cardiomyopathy Questionnaire Clinical Summary Score
no changein humans1
Engage-hf showed no clear effect on kansas City Cardiomyopathy Questionnaire Clinical Summary Score in humans (75.2 (SE 2.6) vs. 72.2 (SE 2.6); p = 0.40).
“KCCQ-23 CSS at 90 days was 75.2 (SE 2.6) in the intervention group versus 72.2 (SE 2.6) in the control group (between-group p = 0.40).”
Human trialrecently hospitalized patients with heart failure, LVEF <50%, and suboptimal guideline-directed medical therapy; compared with usual carepatient-facing mobile app and clinician dashboard90 daysn = 134
Circulation. Heart failure
Medication optimization score
upin humans1
1 study
Medication optimization score
upin humans1
Engage-hf increases medication optimization score in humans (83.7% vs. 74.0%; p = 0.010).
“At 90 days, the adjusted MOS was significantly higher in the ENGAGE-HF group compared to the control group (83.7% vs. 74.0%, p = 0.010).”
Human trialrecently hospitalized patients with heart failure, LVEF <50%, and suboptimal guideline-directed medical therapy; compared with usual carepatient-facing mobile app and clinician dashboard90 daysn = 134
Circulation. Heart failure